T0	KEYPHRASE-NOTYPES 8 15	January
T1	KEYPHRASE-NOTYPES 25 30	April
T2	KEYPHRASE-NOTYPES 37 55	healthy volunteers
T3	KEYPHRASE-NOTYPES 57 65	controls
T4	KEYPHRASE-NOTYPES 71 82	individuals
T5	KEYPHRASE-NOTYPES 90 97	history
T6	KEYPHRASE-NOTYPES 101 113	Lyme disease
T7	KEYPHRASE-NOTYPES 115 123	patients
T8	KEYPHRASE-NOTYPES 137 141	ages
T9	KEYPHRASE-NOTYPES 155 160	years
T10	KEYPHRASE-NOTYPES 177 198	follow-up evaluations
T11	KEYPHRASE-NOTYPES 217 222	April
T12	KEYPHRASE-NOTYPES 233 260	institutional review boards
T13	KEYPHRASE-NOTYPES 264 283	Columbia University
T14	KEYPHRASE-NOTYPES 292 328	New York State Psychiatric Institute
T15	KEYPHRASE-NOTYPES 342 347	study
T16	KEYPHRASE-NOTYPES 357 369	participants
T17	KEYPHRASE-NOTYPES 396 403	consent
T18	KEYPHRASE-NOTYPES 405 416	Evaluations
T19	KEYPHRASE-NOTYPES 439 475	New York State Psychiatric Institute
T20	KEYPHRASE-NOTYPES 480 514	Columbia University Medical Center
T21	KEYPHRASE-NOTYPES 516 526	Treatments
T22	KEYPHRASE-NOTYPES 550 557	patient
T23	KEYPHRASE-NOTYPES 560 564	home
T24	KEYPHRASE-NOTYPES 566 574	Patients
T25	KEYPHRASE-NOTYPES 593 601	criteria
T26	KEYPHRASE-NOTYPES 607 614	history
T27	KEYPHRASE-NOTYPES 618 655	physician-documented erythema migrans
T28	KEYPHRASE-NOTYPES 659 671	U.S. Centers
T29	KEYPHRASE-NOTYPES 676 691	Disease Control
T30	KEYPHRASE-NOTYPES 696 706	Prevention
T31	KEYPHRASE-NOTYPES 708 711	CDC
T32	KEYPHRASE-NOTYPES 721 734	manifestation
T33	KEYPHRASE-NOTYPES 738 750	Lyme disease
T34	KEYPHRASE-NOTYPES 770 785	equivocal ELISA
T35	KEYPHRASE-NOTYPES 799 830	positive Western blot serology6
T36	KEYPHRASE-NOTYPES 838 871	current positive IgG Western blot
T37	KEYPHRASE-NOTYPES 878 903	CDC surveillance criteria
T38	KEYPHRASE-NOTYPES 922 949	single reference laboratory
T39	KEYPHRASE-NOTYPES 951 970	University Hospital
T40	KEYPHRASE-NOTYPES 974 985	Stony Brook
T41	KEYPHRASE-NOTYPES 992 1001	treatment
T42	KEYPHRASE-NOTYPES 1006 1018	Lyme disease
T43	KEYPHRASE-NOTYPES 1035 1040	weeks
T44	KEYPHRASE-NOTYPES 1047 1058	ceftriaxone
T45	KEYPHRASE-NOTYPES 1081 1087	months
T46	KEYPHRASE-NOTYPES 1095 1106	study entry
T47	KEYPHRASE-NOTYPES 1112 1140	subjective memory impairment
T48	KEYPHRASE-NOTYPES 1150 1168	participant report
T49	KEYPHRASE-NOTYPES 1188 1193	onset
T50	KEYPHRASE-NOTYPES 1197 1209	Lyme disease
T51	KEYPHRASE-NOTYPES 1219 1237	objective evidence
T52	KEYPHRASE-NOTYPES 1241 1258	memory impairment
T53	KEYPHRASE-NOTYPES 1280 1306	Wechsler Memory Scale III8
T54	KEYPHRASE-NOTYPES 1321 1324	age
T55	KEYPHRASE-NOTYPES 1327 1330	sex
T56	KEYPHRASE-NOTYPES 1337 1372	education-adjusted population norms
T57	KEYPHRASE-NOTYPES 1380 1394	study criteria
T58	KEYPHRASE-NOTYPES 1435 1456	diagnostic confidence
T59	KEYPHRASE-NOTYPES 1467 1485	antibiotic therapy
T60	KEYPHRASE-NOTYPES 1518 1526	patients
T61	KEYPHRASE-NOTYPES 1540 1549	treatment
T62	KEYPHRASE-NOTYPES 1574 1597	neurologic Lyme disease
T63	KEYPHRASE-NOTYPES 1611 1621	guidelines
